Results 251 to 260 of about 212,634 (323)

Establishment of a novel cynomolgus monkey model of hyperuricemia

open access: yesAnimal Models and Experimental Medicine, EarlyView.
We established a novel hyperuricemia model in cynomolgus monkeys (A) via oral administration of potassium oxonate, hydrochlorothiazide, and adenine mixed in fruits and vegetables. This model (B) targets uric acid synthesis and enzymatic degradation, and (C) regulates renal and intestinal excretion, thereby stably elevating serum uric acid and serving ...
Ji‐Wei Wang   +12 more
wiley   +1 more source

Challenges of modeling pristane‐induced lupus in non‐human primates

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Systemic lupus erythematosus (SLE) in cynomolgus monkeys was modeled by two intraperitoneal injections of pristane at a dose of 3.5 mL/kg, administered at weeks 1 and 23. Serum samples from all monkeys that received pristane tested positive for antinuclear antibodies.
Elena Vladimirovna Vinogradova   +5 more
wiley   +1 more source

Retention of Urine in Children

open access: green, 2011
Fazal Rehman, Hazrat Ullah Khattak
openalex   +1 more source

Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression. Methods This 1‐year, multicenter, prospective study assessed clinical, neuroimaging (3T‐magnetic resonance imaging [MRI], dopamine transporter single‐photon emission ...
Margherita Fabbri   +26 more
wiley   +1 more source

Risk factors for infections after urological procedures among patients with negative urine culture screening. [PDF]

open access: yesAntimicrob Steward Healthc Epidemiol
Tantiwattanapaibul N   +9 more
europepmc   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy